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Background/aim: Thirty male BALB/c mice were equally divided into three groups: control, L. acidophilus, and B. bifidum for the
assessment of the probiotics’ stability in the gut microflora.
Materials and methods: First, the gut microflora of the mice was checked every 3 days (days 3, 6, 9, and 12) without probiotic
consumption, and then the mice were daily given orally 1.5 g of probiotics in 30 cc of drinking water. The consumption of probiotics was
then stopped for recovery and then the consumption continued for 5 months.
Results: On day 9 after the consumption of the probiotics, L. acidophilus and B. bifidum were significantly increased from 4% to 83% and
from 1% to 61%, respectively. L. acidophilus count showed no significant decrease at the end of 5 months compared to day 9 of probiotic
consumption (74%), but B. bifidum count was dramatically decreased to 45% and 36% at the end of 1 and 5 months, respectively.
Conclusion: Our results revealed that, unlike B. bifidum, the amount of L. acidophilus remained almost unchanged in the long term,
indicating more stability of L. acidophilus than B. bifidum in the gut microflora.
Key words: Bifidobacterium bifidum, Lactobacillus acidophilus, probiotic, gut microflora

1. Introduction
The human gastrointestinal (GI) tract is covered with
more than 500 different species of bacteria that can
influence the host’s pathophysiology. Probiotics are the
beneficial nonpathogenic bacteria used as biotherapeutic
agents for the prevention or treatment of some diseases
(1,2). In this regard, the essential point is to demonstrate
a distinct health advantage attained by consumption of a
specific probiotic strain that cannot be compared even to
other strains of the same species (3). Herein, overgrowth
of pathogenic organisms within the GI tract, stimulation
of intestinal immunity, and production of essential
nutrients and/or bioactive food components might be
related to the risk of developing neoplastic diseases such
as cancer (4–6). Thus, gut microflora may influence the
multiple processes associated with a change in cancer
risk, and consequently removal of the inflammatory

bacteria by probiotic agents is a potential mechanism to
modulate disease severity (3,7).
A number of in vitro and in vivo studies have
demonstrated that the consumption of specific probiotics
such as bifidobacterium and lactobacillus can modulate
the intestinal bacteria (8). Undeniably, greater attention
to the duration of beneficial probiotic stability is required
for health promotion (4,9). It seems that based on the
short- and long-term utilization of various probiotics for
gut microflora modification, they can be used in different
approaches regarding various diseases (6). The specific
probiotic strains with short-term storage can be used for
treatment of some disorders such as diarrhea (8,10). The
critical point is to demonstrate the long-term prevention
and treatment of some diseases like cancer that can be
achieved by using specific probiotic strains that can be
replaced and stored long term in the gut (11).
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The aim of the present study was to evaluate the effects
of Bifidobacterium bifidum (B. bifidum) and Lactobacillus
acidophilus (L. acidophilus) probiotics on concentration
of mice gut microflora. Increasing of B. bifidum and
L. acidophilus through specific dietary intervention
of Bla/016P/M and Lac/002P/M probiotics may cause
inhibition of initiation and development of GI disorders.
Moreover, the existence and stability of concentrations
of B. bifidum and L. acidophilus in the gut microflora
should be evaluated during several months of probiotic
consumption.
2. Materials and methods
2.1. Materials
B. bifidum probiotic (Bla/016P/M), from a traditional
product (yogurt), and L. acidophilus probiotic
(Lac/002P/M), from CHR Hansen (La5), were gifted by
Zist Takhmir Supplements Company (Tehran, Iran). BHI
broth (brain heart infusion broth), NAT agar (nalidixic
acid tween agar), and EMB agar (eosin methylene blue
agar) were purchased from Merck KGaA (Darmstadt,
Germany).
2.2. Preparation of media and method of culture
First 3.7 g of BHI broth and 10.5 g of EMB agar powder
were separately dissolved in 100 and 300 cc of water,
respectively, according to the manufacturers’ instructions.
Next, 43 g of NAT agar and 42 g of BHI agar powder were
separately dissolved in 800 cc of water. Then 1 cc of the
resulting solution was taken and the autoclave processing
was done at 121 °C and 15 atmosphere pressure for 15
min. The anaerobic bacteria culture in the fecal sample
was done on NAT agar and BHI agar, and then incubated
in an anaerobic jar using a gas pack system at 37 °C. The
aerobic bacteria culture was performed on EMB agar and
BHI agar, and followed by incubation at 37 °C with the
same dilution.
2.3. Staining assay
Before starting the Gram staining, two slides were prepared
from each culture plate of bacteria. Then a crystal violet
stain was applied to the heat-fixed smear of the bacterial
culture. Heat fixation is mostly used to affix the bacteria to
the slide so that they do not rinse out during the staining

procedure. After that, the sufficient iodine solution was
added in order to bind to crystal violet and trap it in the
cell. The next step was rapid decolorization with ethanol/
acetone. Finally, Safranin was used as a counterstain.
2.4. Animal study
Male inbred BALB/c mice (6–8 weeks old, purchased from
Iran Pasteur Institute) were maintained under 12-h dark
and light cycles, and were given access to food and water
ad libitum. The procedures were done in accordance with
the guidelines for the care and use of laboratory animals of
Tehran University of Medical Sciences.
2.5. Study design
Thirty mice were equally divided into control,
Lac/002P/M, and Bla/016P/M groups for assessment of
the probiotics’ stability in the long term. In this context,
the gut microflora was evaluated every 3 days (days 3,
6, 9, and 12), and then the mice were daily given orally
1.5 g of probiotics (1 × 109 cfu/g Lac/002P/M and 1 ×
109 cfu/g Bla/016P/M) in 30 cc of drinking water over 12
days for gut microflora replacement with the probiotics.
The probiotics consumption was stopped for the same
duration to achieve gut microflora recovery; then the
probiotic feeding continued for 5 months (6).
2.6. Fecal sampling
Fecal samples of mice were collected before and after
treatment in separate sterile tubes including 1 cc of BHI
broth. Different dilutions (1:10, 1:100, and 1:1000) of each
sample were transferred onto a BHI agar plate and cultured
with the standard pour-plate method. After incubation and
comparison of the colony count results, the dilution 1:1000
was selected as the optimum. The optimum specimens
were placed on the selective culture plates and incubated
anaerobically using a gas pack system at 37 °C for 72 h and
aerobically at 37 °C for 24 h with the streak-plate method.
All the bacterial isolates were identified by morphological
study, Gram staining, and different biochemical tests
such as catalase, oxidase, and carbohydrate fermentation
tests (12–16). Moreover, a combination of RT-PCR and
denaturing gradient gel electrophoresis was used for the
validation of L. acidophilus existence in the gut (17,18).
Table 1 shows the sequences of the specific primers used
for this method.

Table 1. The specific primer sequences used for identification of Lactobacillus acidophilus with RT-PCR method.
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Lactobacillus acidophilus

Sequences

P1B16

AGA GTT TGA TCC TGG CTC AG

MLB16

GGC TGC TGG CAC GTA GTT AG

Ss2

CACGGATCCTACGGGTACCTTGTTACGACTT

HE1

AGCAGATCGCATGATCAGCT
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2.7. Statistical analysis
Depending on the number of groups to be compared
within each trial and depending on the P-value of the
Kolmogorov–Smirnov test of normality, a t-test, oneway ANOVA, or a nonparametric test was used for data
analyses. Differences between groups in the bacteria
amounts were estimated by analyzing the area under the
curve. A level of P < 0.05 was considered to be statistically
significant. Statistical analysis was done using SPSS
(version 13.0; SPSS Inc., Chicago, IL, USA).
3. Results
The specific media were used for the aerobic and anaerobic
samples during the pour-plate and the streak-plate
techniques to determine the normal microflora count
in each sample. Identification of normal microflora was
performed by morphological study, Gram staining, and
different biochemical tests. The microflora assay on normal
animals before probiotic consumption was done every 3
days (days 3, 6, 9, and 12) (Tables 2 and 3). In general, it is
notable that 99.6% of microflora were anaerobic bacteria
(of these, the maximum percentage of 52% belonged to
Bacteroides spp.) and 0.4% were aerobic bacteria (68% of
these cases belonged to E. coli).
Microflora concentration in the group consuming
Lac/002P/M probiotics consisted of 99.6% anaerobic
bacteria (with the maximum percentages of 83% and
10.5% for L. acidophilus and Bacteroides spp., respectively)
and 0.4% aerobic bacteria on day 9 of treatment (Table
2). L. acidophilus existence in the gut was verified using a

combination of RT-PCR and DGGE (Figure). Moreover,
99.6% anaerobic bacteria (the maximum rates belonged to
B. bifidum with 61% and Bacteroides spp. with 27%) and
0.4% aerobic bacteria in microflora concentrations were
detected in the group consuming Bla/016P/M on day 9 of
treatment (Table 3). The mean values of B. bifidum and L.
acidophilus populations were significantly increased from
1% and 4% to 61% and 83%, respectively (P < 0.05) (Tables
2 and 3). Moreover, the consumption of the probiotics was
stopped for 12 days to achieve gut microflora recovery. Our
data showed that on day 6 after pausing of the probiotic
feeding, the normal gut microflora returned to its normal
count (the same as before probiotic consumption). The
consumption of the probiotics was continued for 5 months
and microflora assays were performed monthly. At the
end of 1 month of consumption, Lactobacillus acidophilus
remained unchanged (83%) (Table 2), but Bifidobacterium
bifidum was decreased from 61% to 45% (P < 0.05) (Table
3). At the end of 5 months, Lactobacillus acidophilus was
not significantly declined compared to day 9 of probiotic
consumption (83% to 74%) (P > 0.05) (Table 2), but
Bifidobacterium bifidum was significantly decreased from
61% to 36% (P < 0.05) (Table 3).
4. Discussion
The purpose of the present study was to determine
whether persistent consumption of probiotics can
modify the gut microflora in the long term. The results
demonstrated that treatment with Lac/002P/M and
Bla/016P/M probiotics could significantly increase L.

Table 2. Mice microflora concentration before and after Lac/002P/M consumption.
Type of
bacteria
Aerobic

Anaerobic

Total
(%)

Bacteria spp.

Before
Day 9 of
treatment (%) treatment (%)

After 1 month of
treatment (%)

After 5 months of
treatment (%)

≈ 0.4

E.coli

68

68

68

68

Other coliforms

32

32

32

32

Bacteroides spp.

52

10.5

10.5

15.5

Prevotella spp.

14

2.5

2.5

4.5

Clostridium spp.

17

2

2

3

Peptostreptococcus spp.

11

1

Lactobacillus acidophilus

4

83

Bifidobacterium bifidum

1

Other bacteria

1

≈ 99.6

1

1
*

83
1

2
*

74 *
1

Gut microflora was assessed every 3 days (days 3, 6, 9, and 12) after oral probiotic consumption, and then continued for 5 months. On
day 9 of probiotic consumption, Lactobacillus acidophilus was significantly increased from 4% to 83% (P < 0.05), but its count showed no
significant change at the end of 5 months compared to day 9 of probiotic consumption (74%) (P > 0.05). *P < 0.05 compared to before
treatment.
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Table 3. Mice microflora concentration before and after Bla/016P/M consumption.
Type of
bacteria
Aerobic

Anaerobic

Total
(%)

Bacteria spp.

Before
treatment (%)

Day 9 of
treatment (%)

After 1 month of
treatment (%)

After 5 months of
treatment (%)

≈ 0.4

E.coli

68

68

68

68

Other coliforms

32

32

32

32

Bacteroides spp.

52

27

38

42

Prevotella spp.

14

4

9

11

Clostridium spp.

17

4

4

5

Peptostreptococcus spp.

11

3

3

5

Lactobacillus acidophilus

4

Bifidobacterium bifidum

1

61*

45 *, #

36 *, #

Other bacteria

1

1

1

1

≈ 99.6

Gut microflora was assessed every 3 days (days 3, 6, 9, and 12) after oral probiotic consumption, and then continued for 5 months.
Bifidobacterium bifidum was significantly increased from 1% to 61% onday 9 after probiotic consumption (P < 0.05), but was dramatically
decreased to 45% and 36% at the end of 1 and 5 months, respectively (P < 0.05). *P < 0.05 compared to before treatment.
#
P < 0.05 compared to day 9 of probiotic consumption.

Figure. L. acidophilus existence in the gut was verified using
a combination of RT-PCR and denaturing gradient gel
electrophoresis.

692

acidophilus and B. bifidum concentrations from 4% and
1% to 83% and 61%, respectively, in the gut of mice on day
9 of treatment. Existence and remaining of probiotics were
also observed in microflora concentration 1 and 5 months
after consumption of probiotics (83% and 74% for L.
acidophilus and 45% and 36% for B. bifidum, respectively).
Our results revealed that, unlike B. bifidum, L. acidophilus
amount remained almost unchanged during the longterm probiotic consumption. Thus, our data may indicate
more stability of L. acidophilus than B. bifidum in the gut
microflora in the long term.
The collected data from previous studies demonstrated
that alterations in the gut microflora can lead to GI
disorders (19). Dietary components may influence
microflora balance and modification (4,20), which can
in turn reduce the incidence of several problems in the
GI (3). Undeniably, greater attention is needed about
the exposure duration of beneficial probiotics for health
promotion (4,9). It seems that based on the ability of
various probiotics in the gut microflora modification in
the long or short term, they can have different effects on
various diseases. In this regard, several (pre) clinical studies
have demonstrated that the application of probiotics can
have beneficial effects on diarrhea, intestinal infections,
inflammatory bowel disease, and irritable bowel syndrome
(8,21). Studies have shown that using specific probiotic
strains such as B. bifidum can probably be useful for the
treatment of gut-related diseases in the short term (8,10).
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In addition, well-controlled clinical studies have revealed
that L. rhamnosus GG and B. animalis Bb12 probiotics can
reduce the duration of acute rotavirus diarrhea (22,23).
On the other hand, the critical point is to demonstrate
the best and long-term prevention and treatment of
diseases like cancer and polyps (6), which may be achieved
using specific probiotic strains such as L. acidophilus that
can be replaced and stored in the long term in the gut (11).
In our study, a high amount of L. acidophilus was observed
in the gut microflora at the end of 5 months after probiotic
consumption. In this regard, the results of another study
indicated that the long-term presence and remaining
of L. acidophilus can have a critical role in modulating
colorectal cancers (3). An in vivo study demonstrated
that L. acidophilus consumption decreased the ratio of
aberrant crypt foci in rats with a high-fat diet containing
the carcinogen (24). Furthermore, a reduction in tumor
progression in the small intestine was also observed
in mice receiving the probiotic yogurt formulation

containing microencapsulated live L. acidophilus cells
(25). In addition, the gavage of L. acidophilus probiotics
inhibited tumor growth in an orthotopic mouse model of
colon cancer (26). The collected data from the mentioned
studies suggest that the storage of L. acidophilus in the gut
in the long term may be essential for prevention and/or
treatment of gut-related disease including colon cancer.
Finally, the present study demonstrated a greater
stability in L. acidophilus than B. bifidum in the
gut microflora of mice in the long term (5 months)
consumption of probiotics. It seems that based on the
ability of various probiotics to modify the gut microflora
in the long or short term, they can have some beneficial
effects on various gut-related diseases.
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